In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole
- PMID: 6124876
In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole
Abstract
Binding characteristics of astemizole were studied in vitro in various receptor binding models and in vivo by determining the occupancy of histamine H1 receptors in guinea pig lung and cerebellum. In vitro, astemizole was found to have a high affinity for histamine H1 receptors, but great difficulties were encountered in proving this because of its high affinity for nonspecific binding sites. Since the equilibrium conditions were not reached in vitro, the real affinity of astemizole remains unclear and its receptor profile must be interpreted with caution. Nevertheless, the drug is certainly much more potent on histamine H1 receptors than on serotonin S2 and adrenergic alpha 1-receptors. Moreover, it was found to be devoid of antimuscarinic and antidopaminergic properties. The most striking property of this drug is its extremely slow dissociation rate from H1 receptors when assayed in vitro using [3H]-pyrilamine. Ex vivo experiments were performed in guinea pigs; astemizole was given orally to the animals, and the occupancy of H1 receptors in the lung and the cerebellum was determined in vitro by the [3H]-pyrilamine binding assay. Astemizole was found to occupy H1 receptors in lung at very low doses. Here again the most striking receptor binding property was its very long duration. The occupancy of H1 receptors in lung began to decline only 4-6 days after administration of the drug. However, there was a marked difference between the occupancy of peripheral and central receptors; indeed, in contrast to pyrilamine, astemizole at pharmacological doses did not reach the H1 receptors in the cerebellum, presumably because the drug does not readily cross the blood-brain barrier.
Similar articles
-
Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy.Drugs. 1984 Jul;28(1):38-61. doi: 10.2165/00003495-198428010-00003. Drugs. 1984. PMID: 6204835 Review.
-
[Non-sedative antihistaminics and binding to central and peripheral H1 histamine receptors].Allerg Immunol (Paris). 1991 Feb;23(2):51-7. Allerg Immunol (Paris). 1991. PMID: 1677249 French.
-
Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.Mol Pharmacol. 1985 Jun;27(6):600-11. Mol Pharmacol. 1985. PMID: 2860558
-
In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.Arzneimittelforschung. 1995 May;45(5):551-8. Arzneimittelforschung. 1995. PMID: 7612054
-
[Astemizole: its pharmacokinetics and pharmacologic properties].Allerg Immunol (Paris). 1990 Jun;22(6):233-41. Allerg Immunol (Paris). 1990. PMID: 1974137 Review. French.
Cited by
-
Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.Br J Clin Pharmacol. 1984 Jul;18(1):1-8. doi: 10.1111/j.1365-2125.1984.tb05013.x. Br J Clin Pharmacol. 1984. PMID: 6146346 Free PMC article. Clinical Trial.
-
Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever.Thorax. 1984 Sep;39(9):668-72. doi: 10.1136/thx.39.9.668. Thorax. 1984. PMID: 6147905 Free PMC article. Clinical Trial.
-
H1-receptor antagonists. Comparative tolerability and safety.Drug Saf. 1994 May;10(5):350-80. doi: 10.2165/00002018-199410050-00002. Drug Saf. 1994. PMID: 7913608 Review.
-
Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy.Drugs. 1984 Jul;28(1):38-61. doi: 10.2165/00003495-198428010-00003. Drugs. 1984. PMID: 6204835 Review.
-
The time course of action of three differing doses of noberastine, a novel H1-receptor antagonist, on histamine-induced skin wheals and the relationship to plasma drug concentrations in normal human volunteers.Br J Clin Pharmacol. 1993 Feb;35(2):166-70. Br J Clin Pharmacol. 1993. PMID: 8095149 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources